دورية أكاديمية
أعرض في EDS

Modelling the complex nature of the tumor microenvironment: 3D tumor spheroids as an evolving tool.

التفاصيل البيبلوغرافية
العنوان: Modelling the complex nature of the tumor microenvironment: 3D tumor spheroids as an evolving tool.
المؤلفون: Rodrigues DB; 3B's Research Group, I3Bs, Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence On Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, Barco, 4805-017, Guimarães, Portugal.; ICVS/3B's, PT Government Associate Laboratory, Braga, 4805-017, Guimarães, Portugal., Reis RL; 3B's Research Group, I3Bs, Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence On Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, Barco, 4805-017, Guimarães, Portugal.; ICVS/3B's, PT Government Associate Laboratory, Braga, 4805-017, Guimarães, Portugal., Pirraco RP; 3B's Research Group, I3Bs, Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence On Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, Barco, 4805-017, Guimarães, Portugal. rpirraco@i3bs.uminho.pt.; ICVS/3B's, PT Government Associate Laboratory, Braga, 4805-017, Guimarães, Portugal. rpirraco@i3bs.uminho.pt.
المصدر: Journal of biomedical science [J Biomed Sci] 2024 Jan 23; Vol. 31 (1), pp. 13. Date of Electronic Publication: 2024 Jan 23.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 9421567 Publication Model: Electronic Cited Medium: Internet ISSN: 1423-0127 (Electronic) Linking ISSN: 10217770 NLM ISO Abbreviation: J Biomed Sci Subsets: MEDLINE
أسماء مطبوعة: Publication: 2009- : London : BioMed Central
Original Publication: Basel ; New York : S. Karger Medical and Scientific Publishers, c1994-
مواضيع طبية MeSH: Neoplasms*, Animals ; Cell Communication ; Disease Models, Animal ; Extracellular Matrix ; Tumor Microenvironment
مستخلص: Cancer remains a serious burden in society and while the pace in the development of novel and more effective therapeutics is increasing, testing platforms that faithfully mimic the tumor microenvironment are lacking. With a clear shift from animal models to more complex in vitro 3D systems, spheroids emerge as strong options in this regard. Years of development have allowed spheroid-based models to better reproduce the biomechanical cues that are observed in the tumor-associated extracellular matrix (ECM) and cellular interactions that occur in both a cell-cell and cell-ECM manner. Here, we summarize some of the key cellular interactions that drive tumor development, progression and invasion, and how successfully are these interactions recapitulated in 3D spheroid models currently in use in the field. We finish by speculating on future advancements in the field and on how these can shape the relevance of spherical 3D models for tumor modelling.
(© 2024. The Author(s).)
References: Urol Oncol. 2021 May;39(5):302.e9-302.e18. (PMID: 33676847)
Eur J Clin Invest. 2018 Apr;48(4):. (PMID: 29405291)
Sci Signal. 2022 Sep 27;15(753):eaaz4742. (PMID: 36166511)
Cell. 2009 Nov 25;139(5):891-906. (PMID: 19931152)
iScience. 2020 Sep 28;23(10):101621. (PMID: 33089109)
Front Cell Dev Biol. 2021 Mar 12;9:634371. (PMID: 33777943)
Cancer Cell. 2013 Oct 14;24(4):466-80. (PMID: 24075834)
Acta Naturae. 2018 Jan-Mar;10(1):34-42. (PMID: 29713517)
Molecules. 2021 Aug 16;26(16):. (PMID: 34443536)
Int J Mol Sci. 2019 Jul 26;20(15):. (PMID: 31357383)
Nat Protoc. 2018 Sep;13(9):2062-2085. (PMID: 30202107)
Cell Rep. 2021 Jul 27;36(4):109455. (PMID: 34320350)
Front Pharmacol. 2020 Sep 11;11:579068. (PMID: 33041823)
J Biomech. 2022 Nov;144:111346. (PMID: 36252307)
Cancer Res. 2016 Sep 15;76(18):5302-12. (PMID: 27488527)
Annu Rev Cell Dev Biol. 2001;17:463-516. (PMID: 11687497)
Cell Mol Biol Lett. 2021 Jun 26;26(1):30. (PMID: 34174813)
Front Pharmacol. 2018 Jan 23;9:6. (PMID: 29410625)
Small Methods. 2021 May;5(5):e2001207. (PMID: 34928079)
Respirology. 2005 Jan;10(1):2-8. (PMID: 15691231)
Oncogene. 2015 Feb 12;34(7):890-901. (PMID: 24561529)
Sci Rep. 2017 Dec;7(1):45. (PMID: 28246385)
Sci China Life Sci. 2022 Oct;65(10):2031-2049. (PMID: 35366152)
Biomolecules. 2020 Nov 16;10(11):. (PMID: 33207810)
Anticancer Res. 2022 Oct;42(10):4689-4700. (PMID: 36191998)
Cancer Res. 2022 Nov 15;82(22):4179-4190. (PMID: 36066360)
Cancers (Basel). 2021 Jan 15;13(2):. (PMID: 33467651)
Cancer Med. 2016 Nov;5(11):3353-3367. (PMID: 27734632)
J Exp Med. 2019 May 6;216(5):1016-1026. (PMID: 30975895)
BMC Cancer. 2016 May 24;16:331. (PMID: 27220365)
Mol Cancer. 2015 Aug 23;14:162. (PMID: 26298390)
PLoS One. 2013 Dec 27;8(12):e85143. (PMID: 24386459)
J Cell Biol. 2017 Nov 6;216(11):3799-3816. (PMID: 29021221)
Clin Sci (Lond). 2021 Jan 15;135(1):35-52. (PMID: 33399850)
BMC Cancer. 2018 Oct 1;18(1):939. (PMID: 30285678)
Lab Chip. 2022 Jun 28;22(13):2502-2518. (PMID: 35579189)
Oncol Lett. 2018 May;15(5):7000-7006. (PMID: 29731870)
Mol Pharm. 2014 Jul 7;11(7):2016-21. (PMID: 24754837)
Br J Cancer. 1999 Nov;81(5):774-82. (PMID: 10555745)
J Mol Med (Berl). 2014 Dec;92(12):1271-81. (PMID: 25099519)
Nat Methods. 2017 Jul;14(7):743-751. (PMID: 28504681)
Nat Rev Drug Discov. 2003 Sep;2(9):703-16. (PMID: 12951577)
Cancers (Basel). 2022 Oct 05;14(19):. (PMID: 36230799)
J Clin Invest. 1997 May 1;99(9):2246-53. (PMID: 9151798)
Lab Invest. 2006 Aug;86(8):767-80. (PMID: 16732297)
Biochemistry (Mosc). 2018 Dec;83(12):1469-1476. (PMID: 30878022)
Int J Oral Sci. 2021 Mar 1;13(1):6. (PMID: 33649301)
Nat Rev Immunol. 2018 Dec;18(12):773-789. (PMID: 30254251)
Oncotarget. 2016 Jul 19;7(29):45745-45756. (PMID: 27304190)
Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7353-7362. (PMID: 30910979)
Int J Oncol. 2007 Dec;31(6):1403-13. (PMID: 17982667)
Cancers (Basel). 2021 Nov 05;13(21):. (PMID: 34771711)
J Invest Dermatol. 2022 Aug;142(8):2205-2216.e6. (PMID: 35007555)
APMIS. 1988 May;96(5):433-44. (PMID: 3288248)
Acta Biomater. 2022 Jan 15;138:228-239. (PMID: 34718182)
Trends Cell Biol. 2014 Jan;24(1):26-34. (PMID: 24295852)
Mol Cancer Ther. 2016 Oct;15(10):2357-2369. (PMID: 27512118)
J Exp Clin Cancer Res. 2020 Sep 30;39(1):204. (PMID: 32993787)
Oncol Rep. 2020 Aug;44(2):577-588. (PMID: 32627006)
Immunity. 2021 May 11;54(5):859-874. (PMID: 33838745)
Semin Cancer Biol. 2010 Jun;20(3):161-8. (PMID: 20470890)
Cell Motil Cytoskeleton. 2001 Mar;48(3):175-89. (PMID: 11223949)
J Invest Dermatol. 2022 Jan;142(1):201-211. (PMID: 34265328)
J Neurosurg. 1990 Mar;72(3):463-75. (PMID: 2406382)
Cells. 2021 Aug 28;10(9):. (PMID: 34571880)
Cancer Sci. 2020 Jul;111(7):2385-2399. (PMID: 32385953)
Oncotarget. 2017 Feb 7;8(6):9557-9571. (PMID: 27926487)
Biomark Res. 2021 Jun 5;9(1):44. (PMID: 34090526)
Cancer Res. 2018 Feb 15;78(4):950-961. (PMID: 29259017)
Biomaterials. 2020 Apr;238:119853. (PMID: 32062146)
Oncogene. 2006 Oct 26;25(50):6563-73. (PMID: 16715142)
Front Oncol. 2021 Sep 21;11:690618. (PMID: 34621667)
Front Cell Dev Biol. 2021 Nov 30;9:786728. (PMID: 34917620)
Crit Rev Oncol Hematol. 2000 Nov-Dec;36(2-3):75-87. (PMID: 11033298)
PLoS One. 2020 Nov 11;15(11):e0240833. (PMID: 33175874)
Oncotarget. 2022 Feb 18;13:393-407. (PMID: 35198099)
JNCI Cancer Spectr. 2021 Dec 15;6(1):. (PMID: 35047751)
Cell Mol Bioeng. 2019 May 30;12(3):203-214. (PMID: 31719910)
Cancer. 1990 Oct 1;66(7):1596-600. (PMID: 2208011)
Ann N Y Acad Sci. 2004 Apr;1014:155-63. (PMID: 15153430)
Int J Cancer. 1994 Aug 1;58(3):393-9. (PMID: 7519585)
J Biomech. 2022 Aug;141:111229. (PMID: 35933917)
Asian Pac J Cancer Prev. 2022 Jan 01;23(1):39-51. (PMID: 35092370)
Int Immunopharmacol. 2022 Oct;111:109048. (PMID: 35905563)
Oncol Rep. 2015 Jul;34(1):203-10. (PMID: 25998046)
Front Oncol. 2022 Jun 28;12:881207. (PMID: 35837091)
Cancer Res. 1984 Jul;44(7):3090-7. (PMID: 6373002)
ACS Appl Mater Interfaces. 2021 Oct 20;13(41):48478-48491. (PMID: 34633791)
Blood. 2015 Sep 10;126(11):1336-45. (PMID: 26162407)
Elife. 2016 Dec 08;5:. (PMID: 27929373)
Cancer Res. 2008 Apr 1;68(7):2329-39. (PMID: 18381440)
Nat Protoc. 2009;4(3):309-24. (PMID: 19214182)
Int J Mol Sci. 2021 Feb 23;22(4):. (PMID: 33672100)
Biomed Res Int. 2013;2013:546318. (PMID: 23986907)
Mol Biol Cell. 2018 Oct 1;29(20):2378-2385. (PMID: 30091653)
Nat Commun. 2021 Mar 26;12(1):1912. (PMID: 33771989)
Cells. 2020 Mar 04;9(3):. (PMID: 32143517)
Gut. 2023 Feb;72(2):325-337. (PMID: 35705369)
Cell Death Dis. 2018 Mar 7;9(3):382. (PMID: 29515112)
Sci Rep. 2019 Nov 22;9(1):17365. (PMID: 31758153)
Neuropathol Appl Neurobiol. 1995 Oct;21(5):386-91. (PMID: 8632833)
Cancers (Basel). 2018 Dec 21;11(1):. (PMID: 30583482)
Int Immunopharmacol. 2020 Jul;84:106532. (PMID: 32388013)
Pharmacol Ther. 2017 Nov;179:171-187. (PMID: 28564583)
Annu Rev Pathol. 2011;6:95-119. (PMID: 20936938)
Cancer Res. 2009 Sep 1;69(17):7121-9. (PMID: 19706774)
Nat Commun. 2020 Mar 5;11(1):1211. (PMID: 32139701)
Bioessays. 2002 Mar;24(3):280-3. (PMID: 11891765)
Front Immunol. 2018 May 28;9:1170. (PMID: 29892300)
Int J Biochem Cell Biol. 2012 Dec;44(12):2144-51. (PMID: 22981632)
Bioeng Transl Med. 2021 Dec 31;7(2):e10286. (PMID: 35600659)
Sci Rep. 2021 Jan 21;11(1):2048. (PMID: 33479502)
Mol Cancer. 2019 Dec 3;18(1):175. (PMID: 31796058)
J R Soc Interface. 2017 Feb;14(127):. (PMID: 28202590)
J Clin Med. 2022 Sep 15;11(18):. (PMID: 36143062)
Commun Biol. 2022 Aug 1;5(1):758. (PMID: 35915226)
Biotechnol Bioeng. 2003 Jul 20;83(2):173-80. (PMID: 12768623)
Virchows Arch. 2021 Jan;478(1):59-72. (PMID: 33475835)
Mod Pathol. 2011 Jun;24(6):801-9. (PMID: 21317876)
Medicine (Baltimore). 2016 Sep;95(1 Suppl 1):S2-S7. (PMID: 27611934)
Nature. 2022 Sep;609(7929):907-910. (PMID: 36171373)
Cell Tissue Res. 2006 Jun;324(3):411-22. (PMID: 16489443)
Biomaterials. 2012 Dec;33(35):9037-48. (PMID: 22992472)
J Immunol. 2009 Jul 15;183(2):937-44. (PMID: 19553533)
Cell Cycle. 2015;14(4):481-7. (PMID: 25607528)
Cell Stem Cell. 2019 Mar 7;24(3):487-497.e7. (PMID: 30799279)
Science. 1988 Apr 8;240(4849):177-84. (PMID: 2451290)
PLoS One. 2009;4(2):e4632. (PMID: 19247489)
Oncotarget. 2017 Mar 21;8(12):19780-19794. (PMID: 28423623)
Cancer Rep (Hoboken). 2019 Dec;2(6):e1228. (PMID: 32729188)
Nature. 2017 May 4;545(7652):54-59. (PMID: 28445465)
Cell. 2002 Sep 20;110(6):673-87. (PMID: 12297042)
Cancer Res. 2015 Jun 15;75(12):2426-33. (PMID: 25855380)
Micromachines (Basel). 2021 Jun 25;12(7):. (PMID: 34202262)
J Cell Biochem. 2019 Mar;120(3):2782-2790. (PMID: 30321449)
Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15894-9. (PMID: 22967508)
Sci Adv. 2017 Sep 13;3(9):e1700764. (PMID: 28924608)
Cancer Gene Ther. 2022 May;29(5):445-455. (PMID: 34548635)
Oncogene. 2010 Dec 9;29(49):6485-98. (PMID: 20802523)
Nat Commun. 2020 Oct 9;11(1):5120. (PMID: 33037194)
Oncol Lett. 2022 Jul 15;24(3):315. (PMID: 35949600)
Front Oncol. 2014 Dec 18;4:366. (PMID: 25566504)
Neuropathol Appl Neurobiol. 2006 Aug;32(4):419-27. (PMID: 16866987)
Biophys J. 2019 Feb 19;116(4):670-683. (PMID: 30709621)
Adv Healthc Mater. 2022 Jun;11(12):e2102696. (PMID: 35182463)
Biol Chem. 2003 Jun;384(6):863-72. (PMID: 12887053)
Transl Oncol. 2023 Jan;27:101566. (PMID: 36257207)
Cancer Cell Int. 2020 Nov 20;20(1):558. (PMID: 33292274)
Cancer Res. 1995 Oct 1;55(19):4425-31. (PMID: 7545541)
Mol Cancer. 2021 Oct 11;20(1):131. (PMID: 34635121)
Proteome Sci. 2014 Jul 11;12:39. (PMID: 25075203)
Transl Oncol. 2017 Aug;10(4):650-660. (PMID: 28668763)
J Clin Med. 2019 May 09;8(5):. (PMID: 31075939)
Front Immunol. 2019 Jul 31;10:1818. (PMID: 31417576)
PLoS One. 2019 Jun 24;14(6):e0218854. (PMID: 31233557)
Nat Med. 2003 Jun;9(6):669-76. (PMID: 12778165)
Nat Med. 2011 Dec 04;18(1):100-10. (PMID: 22138754)
Int J Mol Sci. 2022 Oct 04;23(19):. (PMID: 36233083)
Cell. 1996 May 31;85(5):683-93. (PMID: 8646777)
J Clin Invest. 2003 Dec;112(12):1776-84. (PMID: 14679171)
Polymers (Basel). 2022 Sep 08;14(18):. (PMID: 36145898)
Int J Oncol. 2004 Nov;25(5):1375-82. (PMID: 15492828)
Trends Cell Biol. 2020 Feb;30(2):133-143. (PMID: 31879153)
EXCLI J. 2019 Jul 17;18:530-539. (PMID: 31611737)
Neoplasia. 2015 Jan;17(1):1-15. (PMID: 25622895)
Cell Oncol (Dordr). 2022 Apr;45(2):309-321. (PMID: 35404029)
Development. 2008 Feb;135(3):579-88. (PMID: 18192284)
Sci Rep. 2016 Nov 11;6:36659. (PMID: 27834402)
Microsyst Nanoeng. 2020 Oct 19;6:93. (PMID: 34567703)
Signal Transduct Target Ther. 2021 Apr 23;6(1):153. (PMID: 33888679)
PLoS One. 2015 Sep 17;10(9):e0137923. (PMID: 26378920)
Front Bioeng Biotechnol. 2021 Jun 09;9:649949. (PMID: 34178955)
Biomed Pharmacother. 2019 Oct;118:109320. (PMID: 31545265)
Sci Rep. 2020 Jun 30;10(1):10597. (PMID: 32606331)
Cells. 2022 Jul 19;11(14):. (PMID: 35883684)
Cell. 1992 Apr 3;69(1):11-25. (PMID: 1555235)
Transl Lung Cancer Res. 2022 Jun;11(6):991-1008. (PMID: 35832452)
Cancer Cell. 2005 Sep;8(3):241-54. (PMID: 16169468)
Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6235-40. (PMID: 21444794)
Cell Biochem Funct. 2015 Jul;33(5):257-65. (PMID: 26153649)
Int J Mol Sci. 2021 Nov 30;22(23):. (PMID: 34884812)
Invasion Metastasis. 1993;13(1):31-7. (PMID: 8407209)
Front Oncol. 2021 Mar 15;11:642761. (PMID: 33791226)
Biosci Rep. 2018 Dec 7;38(6):. (PMID: 30355650)
Pathol Res Pract. 2008;204(10):743-50. (PMID: 18597952)
Sci Rep. 2016 Sep 28;6:34094. (PMID: 27678304)
Int J Oncol. 2020 Jun;56(6):1490-1498. (PMID: 32236635)
Am J Transl Res. 2019 Dec 15;11(12):7471-7478. (PMID: 31934294)
Sci Rep. 2019 Dec 23;9(1):19717. (PMID: 31873199)
Drug Metab Pharmacokinet. 2022 Dec;47:100469. (PMID: 36174354)
J Natl Cancer Inst. 1971 Jan;46(1):113-20. (PMID: 5101993)
J Cancer. 2018 Sep 7;9(18):3326-3333. (PMID: 30271493)
Nat Rev Cancer. 2012 Nov;12(11):767-75. (PMID: 23051844)
Invest Ophthalmol Vis Sci. 2018 Sep 4;59(11):4486-4495. (PMID: 30193324)
Cell Mol Bioeng. 2019 Feb;12(1):1-14. (PMID: 31565083)
Gastroenterology. 2001 Oct;121(4):839-52. (PMID: 11606498)
Exp Cell Res. 2018 Aug 1;369(1):90-104. (PMID: 29753625)
BMC Cancer. 2022 Jan 11;22(1):54. (PMID: 35012470)
Cancer Res. 2004 Apr 15;64(8):2743-50. (PMID: 15087389)
Mol Carcinog. 2008 Jun;47(6):424-35. (PMID: 18041768)
Cancer Metastasis Rev. 2006 Mar;25(1):35-43. (PMID: 16680570)
Front Cell Dev Biol. 2021 Mar 23;9:660609. (PMID: 33834026)
NPJ Precis Oncol. 2021 Apr 12;5(1):29. (PMID: 33846488)
Methods Mol Biol. 2018;1655:145-153. (PMID: 28889384)
EMBO J. 2022 Sep 15;41(18):e109288. (PMID: 36052513)
Mol Med Rep. 2012 Apr;5(4):935-42. (PMID: 22266541)
Front Immunol. 2021 Apr 12;12:659996. (PMID: 33912188)
Phys Rev E. 2019 Jun;99(6-1):062414. (PMID: 31330715)
EMBO Rep. 2014 Dec;15(12):1243-53. (PMID: 25381661)
Biomaterials. 2011 Sep;32(26):6052-8. (PMID: 21640378)
PLoS One. 2013;8(2):e57474. (PMID: 23468994)
Oncogene. 2018 Oct;37(42):5682-5693. (PMID: 29970903)
Cells. 2020 Apr 26;9(5):. (PMID: 32357580)
Int J Oncol. 2016 Jul;49(1):265-75. (PMID: 27176937)
Biochem Biophys Res Commun. 2018 Jan 8;495(2):1930-1935. (PMID: 29248729)
Acta Biomater. 2019 Jan 15;84:280-292. (PMID: 30500449)
Mol Biol Cell. 2011 Jul 15;22(14):2423-35. (PMID: 21613543)
Sci Signal. 2014 Sep 23;7(344):re8. (PMID: 25249658)
معلومات مُعتمدة: ERC-2018-STG-805411 International ERC_ European Research Council
فهرسة مساهمة: Keywords: 3D tumor models; Cancer; Spheroids; Tumor microenvironment
تواريخ الأحداث: Date Created: 20240123 Date Completed: 20240124 Latest Revision: 20240125
رمز التحديث: 20240125
مُعرف محوري في PubMed: PMC10804490
DOI: 10.1186/s12929-024-00997-9
PMID: 38254117
قاعدة البيانات: MEDLINE
الوصف
تدمد:1423-0127
DOI:10.1186/s12929-024-00997-9